South Korea
· Delayed Price · Currency is KRW PanGen Biotech Statistics
Total Valuation
PanGen Biotech has a market cap or net worth of KRW 54.28 billion. The enterprise value is 51.22 billion.
| Market Cap | 54.28B |
| Enterprise Value | 51.22B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
PanGen Biotech has 11.41 million shares outstanding. The number of shares has increased by 2.12% in one year.
| Shares Outstanding | 11.41M |
| Shares Change (YoY) | +2.12% |
| Shares Change (QoQ) | +11.64% |
| Owned by Insiders (%) | 4.36% |
| Owned by Institutions (%) | n/a |
| Float | 6.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.65 |
| PB Ratio | 3.22 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -18.40 |
| EV / Sales | 4.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -55.98 |
Financial Position
The company has a current ratio of 2.61, with a Debt / Equity ratio of 0.13.
| Current Ratio | 2.61 |
| Quick Ratio | 1.22 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.39 |
| Interest Coverage | -7.68 |
Financial Efficiency
Return on equity (ROE) is -17.07% and return on invested capital (ROIC) is -8.70%.
| Return on Equity (ROE) | -17.07% |
| Return on Assets (ROA) | -6.59% |
| Return on Capital (ROIC) | -8.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.46 |
| Inventory Turnover | 1.11 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.24% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -24.24% |
| 50-Day Moving Average | 4,216.00 |
| 200-Day Moving Average | 5,514.03 |
| Relative Strength Index (RSI) | 58.76 |
| Average Volume (20 Days) | 102,486 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PanGen Biotech had revenue of KRW 11.13 billion and -2.78 billion in losses. Loss per share was -268.60.
| Revenue | 11.13B |
| Gross Profit | 2.72B |
| Operating Income | -2.54B |
| Pretax Income | -2.74B |
| Net Income | -2.78B |
| EBITDA | -1.00B |
| EBIT | -2.54B |
| Loss Per Share | -268.60 |
Balance Sheet
The company has 5.25 billion in cash and 2.19 billion in debt, giving a net cash position of 3.06 billion or 267.89 per share.
| Cash & Cash Equivalents | 5.25B |
| Total Debt | 2.19B |
| Net Cash | 3.06B |
| Net Cash Per Share | 267.89 |
| Equity (Book Value) | 16.83B |
| Book Value Per Share | 1,474.48 |
| Working Capital | 9.30B |
Cash Flow
In the last 12 months, operating cash flow was -617.91 million and capital expenditures -297.10 million, giving a free cash flow of -915.00 million.
| Operating Cash Flow | -617.91M |
| Capital Expenditures | -297.10M |
| Free Cash Flow | -915.00M |
| FCF Per Share | -80.16 |
Margins
Gross margin is 24.43%, with operating and profit margins of -22.79% and -25.01%.
| Gross Margin | 24.43% |
| Operating Margin | -22.79% |
| Pretax Margin | -24.58% |
| Profit Margin | -25.01% |
| EBITDA Margin | -9.00% |
| EBIT Margin | -22.79% |
| FCF Margin | -8.22% |
Dividends & Yields
PanGen Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.12% |
| Shareholder Yield | -2.12% |
| Earnings Yield | -5.65% |
| FCF Yield | -1.69% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PanGen Biotech has an Altman Z-Score of 2.2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.2 |
| Piotroski F-Score | n/a |